Drs. Do and Rahimy discuss treatment burden in patients with neovascular age-related macular degeneration as well as three patient cases.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
First-Generation Anti-VEGFs: Treatment Burden
Media formats available:
Details
Presenters
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Discuss the considerations involved in the choice of anti-VEGF agent and tailoring treatment regimens for individual patients
- Evaluate clinical evidence for biomarkers that are prognostic of optimal visual outcomes
Accreditation
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
Diana V. Do, MD
Vice Chair of Clinical Affairs
Professor of Ophthalmology
Byers Eye Institute
Stanford University School of Medicine
Palo Alto, CA
Ehsan Rahimy, MD
Department of Ophthalmology
Palo Alto Medical Foundation
Palo Alto, CA
President and Cofounder, HealTheia
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.The following faculty/staff members have the following financial relationships with ineligible companies.
Diana V. Do, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Apellis Pharmaceuticals, Boehringer Ingelheim, Genentech, Iveric Bio, Kodiak Sciences, Kriya, and Regeneron. Grant/Research Support: Belite Bio, Boehringer Ingelheim, Kriya, and Regeneron. Shareholder: Kodiak Sciences.
Ehsan Rahimy, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Apellis Pharmaceuticals, Genentech, and Regeneron. Speaker's Bureau: AbbVie, Apellis Pharmaceuticals, Genentech, and Regeneron.
The Evolve staff and planners have no financial relationships with ineligible companies.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals, Inc.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- MinuteCE®
Photobiomodulation: A Non-Invasive Treatment for Ocular Disease and Trauma
1.00 program credit
Janis T. Eells, Ph.D.
David Boyer, MD
Marion Munk, MD, Ph.D
Marion Munk, MD, Ph.D
Diana V. Do, MD
Diana V. Do, MD
Marion Munk, MD, Ph.D
